

Acute Lymphoblastic Lymphoma

Relapsed or Refractory




CCT5079
Phase Ib Study of
Brexucabtagene
Autoleucel plus
Dasatinib in Adults
with Acute
Lymphoblastic
Leukemia




PI: Muffly
Sponsor: Stanford
University



CCT5084
Phase I/II
Dose-Exploration
& Dose-Expansion
Study Evaluating
the Safety and
Efficacy of
Multiplex Base-
Edited Allogeneic
Anti-CD7 CAR-T
Cells (BEAM-201)
in Relapsed /
Refractory T-Cell
Acute
Lymphoblastic
Leukemia (T-ALL)
or T-Cell
Lymphoblastic
Lymphoma (T-LL)

PI: Weng
Sponsor: Beam
Therapeutics Inc.

KEY

-  Pending
-  Open for Enrollment
-  Observational Study

-  Optional Path
-  [Link](#) Trial Posting
-  Enrollment on Hold

-  Extension Study
-  Immunotherapy